BioSyent Releases Financial Results for Q3 and YTD 2024
BioSyent Releases Financial Results for Q3 and YTD 2024
The CEO's presentation on the Q3 and YTD 2024 Results is available at the following link: MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2024. Key highlights include:
安大略省密西沙加，2024年11月20日（環球新聞）-- BioSyent Inc.（"BioSyent"，TSX創業公司：RX）今天發佈了截至2024年9月30日的三個月（Q3）和九個月（YTD）的財務業績。主要亮點包括：
| (CAD) | Q3 2024 |
% Change vs. Q3 2023 |
YTD 2024 |
% Change vs. YTD 2023 |
Trailing Twelve Months (TTM) Sept 30, 2024 |
% Change vs. TTM Sept 30, 2023 |
||||||
| Canadian Pharma Sales | 8,303,074 | +12% | 24,384,698 | +13% | 32,373,796 | +12% | ||||||
| Total Company Sales | 9,556,011 | +8% | 26,234,213 | +13% | 34,507,899 | +12% | ||||||
| EBITDA1 | 2,849,636 | -2% | 7,101,900 | +13% | 8,752,201 | +12% | ||||||
| Net Income After Taxes (NIAT) | 2,307,894 | -2% | 5,656,910 | +13% | 7,107,701 | +14% | ||||||
| Fully Diluted EPS | 0.20 | -% | 0.48 | +17% | 0.60 | +18% |
| （加元） | 2024年第三季度 | % 變化與 2023年第三季度 |
2024年迄今爲止 | 相較於 2023年迄今爲止 |
截至2024年9月30日的過去十二個月 | 相較於 截至2023年9月30日的TTm |
||||||
| 加拿大藥品銷售 | 8,303,074 | +12% | 24,384,698 | +13% | 32,373,796 | +12% | ||||||
| 公司總銷售額 | 9,556,011 | +8% | 26,234,213 | +13% | 34,507,899 | +12% | ||||||
| EBITDA1 | 2,849,636 | -2% | 7,101,900 | +13% | 8,752,201 | +12% | ||||||
| 稅後淨利潤（NIAT） | 2,307,894 | -2% | 5,656,910 | +13% | 7,107,701 | +14% | ||||||
| 攤薄後每股收益 | 0.20 | -% | 0.48 | +17% | 0.60 | +18% |
- Return on Average Equity for TTM September 30, 2024 was 20% as compared to 18% for TTM September 30, 2023
- During YTD 2024, repurchased for cancellation a total of 162,300 common shares under a Normal Course Issuer Bid (NCIB)
- Paid quarterly cash dividends of $0.045 per common share on March 15, 2024, June 15, 2024, and September 15, 2024
- Declared subsequent cash dividend of $0.045 per common share to be paid on December 16, 2024
- During Q3 2024, acquired Tibelia / Tibella - tibolone ("Tibelia") global rights, related assets, and operating business
- Tibelia acquisition expected to generate revenue and incremental EBITDA starting in Q1 2025
- 截至2024年9月30日的平均股本回報率爲20%，而截至2023年9月30日爲18%。
- 在2024年度至今，根據正常課程發行者競標(NCIB)，共回購了162,300股普通股用於註銷
- 在2024年3月15日、2024年6月15日和2024年9月15日支付每股普通股現金分紅$0.045。
- 宣佈將在2024年12月16日支付每股普通股現金分紅$0.045
- 在2024年第三季度，收購了Tibelia / Tibella - 噻託酮（"Tibelia"）全球權利、相關資產和業務運營
- 預計Tibelia收購將在2025年第一季度開始產生營收和逐步EBITDA增長
"We are pleased to report our highest-ever quarterly total Company sales in Q3 2024 with 8% growth over the comparative Q3 2023 and 7% growth over the prior quarter, Q2 2024," said René Goehrum, President and CEO of BioSyent. "With 12% sales growth in Canadian pharmaceutical sales, all of the Company's Canadian pharmaceutical products contributed to this growth during the quarter. On a year-to-date basis, our total Company sales, EBITDA and NIAT all grew by 13%. On a per share basis, as a result of our ongoing share buybacks, diluted EPS increased by 17% to $0.48 for the year-to-date period."
"我們很高興報告2024年第三季度公司的總銷售額創下歷史新高，與2023年第三季度相比增長了8%，與上一個季度2024年第二季度相比增長了7%，" BioSyent的總裁兼首席執行官René Goehrum說道。"在加拿大藥品銷售方面增長了12%，公司的所有加拿大藥品產品在這一季度都對這一增長做出了貢獻。按年初至今的基礎計算，我們公司的總銷售額、EBITDA和淨利潤均增長了13%。由於我們持續的股票回購，每股攤薄後每股收益同比增長了17%，達到$0.48。"
Mr. Goehrum continued, "While we continued to deliver profitable growth during the quarter, we also made investments in future growth with continued promotion of our three in-market launch products, FeraMAX Pd Maintenance 45, Inofolic, and Gelclair, as well as development of a new FeraMAX Pd product and regulatory support of a new endocrinology product in-licensed earlier this year. During the quarter, we also made a significant investment in acquiring Tibelia at an attractive valuation. We continue to transition this business to our operating structure and look forward to shipping product in Q1 2025 to fill existing customer orders. With the revenue and EBITDA we expect the Tibelia business to generate, the capital deployed in this transaction delivers on our strategic objectives of long-term growth and portfolio diversification. I look forward to reporting on our continued progress during the rest of 2024 and 2025."
Goehrum先生繼續說道："雖然我們在本季度繼續實現盈利增長，但我們也對未來的增長進行了投資，繼續推廣我們的三款已上市產品，FeraMAX Pd Maintenance 45、Inofolic和Gelclair，以及開發一款新的FeraMAX Pd產品和支持今年早些時候獲得許可的新內分泌產品的監管工作。在本季度，我們還在以吸引人的估值收購Tibelia方面進行了重要投資。我們繼續將這項業務轉變爲公司的運營結構，並期待在2025年第一季度發貨以滿足現有客戶訂單。基於我們預計Tibelia業務將帶來的營業收入和EBITDA，此次交易中投入的資金實現了我們長期增長和投資組合多元化的戰略目標。我期待在2024年和2025年繼續報告我們的進展。"
The CEO's presentation on the Q3 and YTD 2024 Results is available at the following link:
首席執行官關於2024年第三季度和年至今財務結果的報告可以在以下鏈接查看：
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2024 and 2023 will be posted on on November 20, 2024.
公司的截至2024年9月30日和2023年9月30日的三個月和九個月的中期未經審計的簡明合併財務報表和管理層討論與分析將於2024年11月20日發佈。
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit .
有關TSX創業公司交易所的直接市場報價和其他公司財務信息，請訪問。
About BioSyent Inc.
關於BioSyent公司。
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
BioSyent在TSX創業公司交易所上市，標的爲"RX"，是一家盈利增長導向的專業藥品公司，專注於引進或收購那些經過成功開發、安全有效，並且有助於改善患者生活的創新藥品及其他醫療產品。BioSyent通過其社區、專業和國際業務單位來支持治療這些患者的醫療專業人員，營銷其產品。
As of the date of this press release, the Company has 11,594,101 common shares outstanding.
截至本新聞稿發佈之日，公司已發行普通股11,594,101股。
| BioSyent Inc. | ||||||||||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||||||||||
| In Canadian Dollars | Q3 2024 | Q3 2023 | % Change | YTD 2024 | YTD 2023 | % Change | ||||||||
| Net Revenues | 9,556,011 | 8,871,122 | 8% | 26,234,213 | 23,316,616 | 13% | ||||||||
| Cost of Goods Sold | 2,069,596 | 1,809,024 | 14% | 5,533,089 | 4,423,178 | 25% | ||||||||
| Gross Profit | 7,486,415 | 7,062,098 | 6% | 20,701,124 | 18,893,438 | 10% | ||||||||
| Operating Expenses and Finance Income/Costs | 4,511,311 | 3,999,903 | 13% | 13,169,535 | 12,214,323 | 8% | ||||||||
| Net Income Before Tax | 2,975,104 | 3,062,195 | -3% | 7,531,589 | 6,679,115 | 13% | ||||||||
| Tax (including Deferred Tax) | 667,210 | 711,295 | -6% | 1,874,679 | 1,669,779 | 12% | ||||||||
| Net Income After Tax | 2,307,894 | 2,350,900 | -2% | 5,656,910 | 5,009,336 | 13% | ||||||||
| Net Income After Tax % to Net Revenues | 24% | 27% | 22% | 21% | ||||||||||
| EBITDA | 2,849,636 | 2,899,612 | -2% | 7,101,900 | 6,276,177 | 13% | ||||||||
| EBITDA % to Net Revenues | 30% | 33% | 27% | 27% | ||||||||||
| 1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. | ||||||||||||||
| BioSyent公司。 | ||||||||||||||
| 未經審核的綜合收益臨時簡明報表 | ||||||||||||||
| 以加元計算 | 2024年第三季度 | 2023年第三季度 | % 變動 | 截至2024年 | 截至2023年 | % 變動 | ||||||||
| 淨收入 | 9,556,011 | 8,871,122 | 8% | 26,234,213 | 23,316,616 | 13% | ||||||||
| 營業成本 | 2,069,596 | 1,809,024 | 14% | 5,533,089 | 4,423,178 | 25% | ||||||||
| 毛利潤 | 7,486,415 | 7,062,098 | 6% | 20,701,124 | 18,893,438 | 10% | ||||||||
| 營業費用和財務收入/費用 | 4,511,311 | 3,999,903 | 13% | 13,169,535 | 12,214,323 | 8% | ||||||||
| 稅前淨利潤 | 2,975,104 | 3,062,195 | -3% | 7,531,589 | 6,679,115 | 13% | ||||||||
| 稅費（包括遞延稅） | 667,210 | 711,295 | -6% | 1,874,679 | 1,669,779 | 12% | ||||||||
| 稅後淨利潤 | 2,307,894 | 2,350,900 | -2% | 5,656,910 | 5,009,336 | 13% | ||||||||
| 稅後淨利潤佔營業收入的百分比 | 24% | 27% | 22% | 21% | ||||||||||
| 息稅折舊攤銷前利潤 | 2,849,636 | 2,899,612 | -2% | 7,101,900 | 6,276,177 | 13% | ||||||||
| 息稅折舊攤銷前利潤佔淨收入的百分比 | 30% | 33% | 27% | 27% | ||||||||||
| 1. EBITDA是一項非國際財務報告準則（IFRS）財務指標。 EBITDA這一術語在國際財務報告準則（IFRS）下沒有標準化的含義，因此可能與其他公司提供的類似指標不可比擬。公司將EBITDA定義爲在利息收入或支出、所得稅、折舊和攤銷之前的收益。 | ||||||||||||||
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | September 30, 2024 | December 31, 2023 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 17,064,865 | $ | 26,187,011 | -35% | |
| Trade and other receivables | 4,342,441 | 3,477,096 | 25% | |||
| Inventory | 5,659,593 | 5,894,495 | -4% | |||
| Prepaid expenses and deposits | 391,940 | 243,460 | 61% | |||
| Loans receivable - current | 68,917 | 69,419 | -1% | |||
| Derivative asset | 22,252 | - | ||||
| CURRENT ASSETS | 27,550,008 | 35,871,481 | -23% | |||
| Long term investments | 10,496,713 | 2,500,000 | 320% | |||
| Property and equipment | 1,254,710 | 1,439,930 | -13% | |||
| Intangible assets | 5,711,094 | 1,152,876 | 395% | |||
| Loans receivable - non current | 156,926 | 205,182 | -24% | |||
| Deferred tax asset | 301,224 | 359,470 | -16% | |||
| TOTAL NON CURRENT ASSETS | 17,920,667 | 5,657,458 | 216% | |||
| TOTAL ASSETS | $ | 45,470,675 | $ | 41,528,939 | 9% | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 7,034,216 | $ | 5,533,850 | 27% | |
| NON CURRENT LIABILITIES | 1,090,207 | 1,235,333 | -12% | |||
| Long term debt | - | - | 0% | |||
| Total Equity | 37,346,252 | 34,759,756 | 7% | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 45,470,675 | $ | 41,528,939 | 9% | |
| BioSyent公司。 | ||||||
| 期間未經審計的簡明合併財務狀況表 | ||||||
| 截至 | 2024年9月30日 | 2023年12月31日 | % 變動 | |||
| 資產 | ||||||
| 向我們的收益金額在扣除支出之前，不考慮事先執行已獲得附權證或普通權證。 | $ | 17,064,865 | $ | 26,187,011 | -35% | |
| 交易及其他應收款 | 4,342,441 | 3,477,096 | 25% | |||
| 庫存 | 5,659,593 | 5,894,495 | -4% | |||
| 預付費用和存款 | 391,940 | 243,460 | 61% | |||
| 應收貸款 - 流動 | 68,917 | 69,419 | -1% | |||
| 衍生資產 | 22,252 | - | ||||
| 流動資產 | 27,550,008 | 35,871,481 | -23% | |||
| 長期投資 | 10,496,713 | 2,500,000 | 320% | |||
| 房地產和設備 | 1,254,710 | 1,439,930 | -13% | |||
| 無形資產 | 5,711,094 | 1,152,876 | 395% | |||
| 應收貸款 - 非流動 | 156,926 | 205,182 | -24% | |||
| 遞延所得稅資產 | 301,224 | 359,470 | -16% | |||
| 總非流動資產 | 17,920,667 | 5,657,458 | 216% | |||
| 總資產 | $ | 45,470,675 | $ | 41,528,939 | 9% | |
| 負債和股東權益 | ||||||
| 流動負債 | $ | 7,034,216 | $ | 5,533,850 | 27% | |
| 非流動負債 | 1,090,207 | 1,235,333 | -12% | |||
| 長期債務 | - | - | 0% | |||
| 總資產 | 37,346,252 | 34,759,756 | 7% | |||
| 總負債和股東權益 | $ | 45,470,675 | $ | 41,528,939 | 9% | |
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
如需進一步信息，請聯繫：
雷內·C·戈亨
董事會主席兼首席執行官
BioSyent公司
電子郵件: investors@biosyent.com
電話: 905-206-0013
網站:
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
本新聞稿可能包含前瞻性的信息或聲明。此處內容代表我們在發佈時的判斷，並且受到風險和不確定性的影響，這些風險和不確定性可能導致實際結果或成果與前瞻性信息或聲明有實質性差異。潛在風險可能包括但不限於與臨床試驗、產品開發、未來收入、運營、盈利能力以及獲得監管批准相關的風險。無論是TSX創業公司交易所還是其監管服務提供者（該術語在TSX創業公司交易所的政策中有定義）均不對本新聞稿的充足性或準確性承擔責任。
